Capital International Sarl - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.

Quarter-by-quarter ownership
Capital International Sarl ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2022$810,000
-22.6%
19,565
+11.6%
0.06%
-22.6%
Q2 2022$1,046,000
-10.4%
17,530
+9.0%
0.08%
+44.8%
Q1 2022$1,168,000
-60.1%
16,084
-53.8%
0.06%
-58.6%
Q4 2021$2,927,000
+265.4%
34,806
+292.1%
0.14%
+97.2%
Q3 2021$801,000
-17.8%
8,876
-13.2%
0.07%
-15.5%
Q2 2021$975,000
-17.2%
10,225
-1.1%
0.08%
-25.0%
Q1 2021$1,177,000
-28.8%
10,334
-13.5%
0.11%
-35.3%
Q4 2020$1,653,000
+79.3%
11,942
+6.5%
0.17%
+53.1%
Q3 2020$922,000
+9.6%
11,212
+4.3%
0.11%
+0.9%
Q2 2020$841,000
+108.2%
10,749
+18.3%
0.11%
+51.4%
Q1 2020$404,000
-77.1%
9,090
-78.0%
0.07%
-72.9%
Q4 2019$1,762,000
+10.7%
41,249
+10.9%
0.27%
-0.4%
Q3 2019$1,591,000
-51.8%
37,200
-28.5%
0.27%
-40.4%
Q2 2019$3,302,000
-35.1%
52,000
-29.1%
0.46%
-27.6%
Q1 2019$5,084,000
+64.5%
73,300
+3.1%
0.64%
+70.7%
Q4 2018$3,091,000
-51.2%
71,100
-14.3%
0.37%
-38.4%
Q3 2018$6,336,000
+25.1%
83,000
+25.9%
0.60%
+17.7%
Q2 2018$5,066,000
-7.0%
65,900
-38.3%
0.51%
-1.9%
Q1 2018$5,448,000
+9.9%
106,8500.0%0.52%
+13.0%
Q4 2017$4,956,000
-27.5%
106,850
-16.7%
0.46%
-18.5%
Q3 2017$6,834,000
-11.5%
128,320
+3.2%
0.57%
-14.8%
Q2 2017$7,722,000
+6.0%
124,320
+15.7%
0.67%
+6.2%
Q1 2017$7,283,000
+14.1%
107,450
+18.4%
0.63%
+7.4%
Q4 2016$6,381,000
+5.5%
90,750
+6.5%
0.58%
+14.3%
Q3 2016$6,048,00085,2500.51%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders